Tidemark’s VanEck Pharmaceutical ETF PPH Stock Holding History

Tidemark’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.8K	Buy	537 +15	+3%	+$1.55K	0.01%	286
2026 Q1	$54.2K	Buy	522 +9	+2%	+$959	0.01%	261
2025 Q4	$52.9K	Buy	513 +2	+0.4%	+$195	0.02%	235
2025 Q3	$46.2K	Buy	511 +25	+5%	+$2.19K	0.01%	260
2025 Q2	$42.7K	Buy	486 +36	+8%	+$3.12K	0.01%	262
2025 Q1	$41K	Sell	450 -733	-62%	-$66K	0.02%	272
2024 Q4	$102K	Buy	1,183 +654	+124%	+$59.2K	0.04%	173
2024 Q3	$50.4K	Hold	529	–	–	0.02%	228
2024 Q2	$48.4K	Buy	+529	New	+$47.2K	0.02%	216

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Tidemark's PPH Position: Q2 2026 in Review

Tidemark increased its VanEck Pharmaceutical ETF (PPH) stake by 2.9% in Q2 2026, buying an estimated $1.55K and bringing the position to 537 shares worth $58.8K. The position accounts for 0.01% of the portfolio, ranked #286.

Tidemark first reported a position in PPH in Q2 2024 and has held it in 9 quarters since. The position peaked at $102K in Q4 2024. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Tidemark held 537 shares of VanEck Pharmaceutical ETF worth $58.8K as of Q2 2026.
Tidemark bought 15 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $1.55K.
VanEck Pharmaceutical ETF made up 0.01% of Tidemark's portfolio in Q2 2026, its #286 holding.
Tidemark first reported a position in VanEck Pharmaceutical ETF in Q2 2024 and has held it in 9 quarters since.
Tidemark's VanEck Pharmaceutical ETF position peaked at $102K in Q4 2024.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.